Interpreting the crosstalk between IL‐17 and PASMCs is crucial to better understand the pathogenesis of CTD‐PAH and to provide evidence for anti‐IL‐17 as a potential therapeutic strategy. Here, IL17A is linked to pulmonary arterial hypertension.